Latest Compliance News

Horizon Minerals has successfully raised $4.65 million through a Share Purchase Plan, supplementing a recent $175 million placement as it advances its Black Swan processing hub development.

WA Kaolin Limited reported a $5.06 million half-year loss despite a 257% revenue surge, grappling with operational setbacks and regulatory challenges. The company’s recent debt restructuring and trading suspension signal a critical juncture as it seeks to stabilise and recapitalise.

IperionX Limited has denied any undisclosed information following a sharp share price drop from $6.93 to $4.58, clarifying its accounting for U.S. government grants amid market volatility.

Coles Group Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.41 per share payable on 30 March 2026, with flexible currency payment options for shareholders.

Kina Securities Limited has launched its inaugural unsecured subordinated bond issue worth PGK 235 million, offering a fixed 7.55% coupon over 10 years, marking a significant step in Papua New Guinea's capital markets.

Classic Minerals has engaged AFDC to conduct a strategic review and is raising A$3 million to advance exploration at its Forrestania gold project and support its ASX relisting efforts.

Variscan Mines has obtained Supreme Court approval to rectify a delayed cleansing notice related to a major share issue, paving the way for trading to resume. The company has also committed to strengthening its compliance procedures following the oversight.

H&G High Conviction Limited has been suspended from ASX trading due to failing to meet operational requirements, raising questions about its future as a listed entity.

Lithium Energy Limited has revealed a detailed two-year, $36 million plan to advance its battery minerals projects, supported by a robust $68 million cash position as it prepares for ASX relisting.

Latitude Group Holdings is considering launching a new Capital Notes 2 offer, potentially allowing existing CN1 holders to reinvest. The offer will require applications through appointed Syndicate Brokers under updated regulatory rules.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

ABx Group has announced a breakthrough with its second mixed rare earth carbonate sample from Tasmania’s Deep Leads deposit, boasting higher heavy rare earth content and fewer impurities. This advancement enhances project flexibility and strengthens ABx’s position in the competitive rare earths market.